Yong Xia Selected Research

Trifluoperazine (Stelazine)

1/2021	Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux.
1/2019	Antipsychotic Drug Trifluoperazine Suppresses Colorectal Cancer by Inducing G0/G1 Arrest and Apoptosis.
1/2018	The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yong Xia Research Topics

Disease

71	Neoplasms (Cancer) 12/2022 - 05/2007
36	Neoplasm Metastasis (Metastasis) 06/2022 - 08/2010
31	Hepatocellular Carcinoma (Hepatoma) 05/2022 - 05/2007
16	Inflammation (Inflammations) 06/2022 - 09/2003
11	Infections 01/2022 - 01/2012
11	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2014
9	Stomach Neoplasms (Stomach Cancer) 01/2022 - 12/2013
9	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2014
8	Fibrosis (Cirrhosis) 01/2022 - 07/2013
8	Cholangiocarcinoma 01/2022 - 03/2013
6	Urinary Bladder Neoplasms (Bladder Cancer) 05/2022 - 07/2018
6	Sepsis (Septicemia) 12/2021 - 05/2006
6	Thrombosis (Thrombus) 01/2021 - 12/2016
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 11/2007
5	Carcinogenesis 01/2022 - 04/2016
5	Myocardial Infarction 01/2021 - 11/2017
5	Atherosclerosis 04/2020 - 11/2007
4	Prostatic Neoplasms (Prostate Cancer) 12/2021 - 09/2017
4	Tuberculosis (Tuberculoses) 01/2020 - 03/2013
3	Melanoma (Melanoma, Malignant) 06/2022 - 02/2016
3	Disease Progression 01/2022 - 11/2018
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 09/2021 - 07/2013
3	Hypoxia (Hypoxemia) 01/2021 - 07/2019
3	Triple Negative Breast Neoplasms 12/2020 - 01/2018
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2020 - 09/2007
3	Heart Failure 01/2020 - 11/2009
3	Lung Neoplasms (Lung Cancer) 01/2020 - 11/2008
3	Stroke (Strokes) 03/2019 - 01/2018
2	Bipolar Disorder (Manic Depressive Psychosis) 09/2022 - 08/2022
2	Type 2 Diabetes Mellitus (MODY) 06/2022 - 01/2019
2	Proteinuria 06/2022 - 01/2019
2	Ascites 05/2022 - 01/2019
2	Diarrhea 01/2022 - 12/2010
2	Hyperglycemia 01/2022 - 04/2020
2	Hyperplasia 01/2022 - 10/2019
2	Hypertension (High Blood Pressure) 01/2022 - 08/2020

Drug/Important Bio-Agent (IBA)

18	Pharmaceutical PreparationsIBA 01/2022 - 01/2011
14	Biomarkers (Surrogate Marker)IBA 12/2022 - 08/2015
11	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2011
8	Antipsychotic Agents (Antipsychotics)IBA 07/2022 - 01/2018
6	MicroRNAs (MicroRNA)IBA 05/2022 - 01/2014
5	CytokinesIBA 01/2022 - 03/2014
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 09/2008
5	Interleukin-8 (Interleukin 8)IBA 01/2022 - 12/2013
5	Messenger RNA (mRNA)IBA 06/2021 - 01/2011
5	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2021 - 09/2003
5	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 01/2020 - 10/2014
5	Antiviral Agents (Antivirals)IBA 01/2019 - 03/2015
4	nifuroxazide (Akabar)IBA 06/2022 - 02/2016
4	Circular RNAIBA 01/2022 - 01/2019
4	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 01/2021 - 09/2007
4	VaccinesIBA 01/2020 - 01/2012
4	Biological ProductsIBA 12/2019 - 09/2014
4	CarcinogensIBA 10/2019 - 01/2015
4	Fetal Proteins (Fetoprotein)IBA 01/2019 - 04/2016
4	Urokinase Plasminogen Activator ReceptorsIBA 07/2018 - 10/2014
4	Therapeutic UsesIBA 09/2017 - 10/2010
3	FlavonoidsIBA 06/2022 - 04/2015
3	BilirubinIBA 05/2022 - 11/2017
3	InflammasomesIBA 01/2022 - 01/2019
3	CateninsIBA 10/2021 - 01/2021
3	Trifluoperazine (Stelazine)FDA LinkGeneric 01/2021 - 01/2018
3	EnzymesIBA 01/2021 - 02/2016
3	Small Interfering RNA (siRNA)IBA 01/2021 - 01/2011
3	PhytochemicalsIBA 01/2021 - 04/2015
3	Matrix Metalloproteinases (MMPs)IBA 12/2020 - 02/2016
3	Long Noncoding RNAIBA 10/2020 - 11/2018
3	LipidsIBA 04/2020 - 11/2007
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 04/2016
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 08/2010
3	RON proteinIBA 01/2020 - 04/2015
3	Carcinoembryonic AntigenIBA 07/2017 - 03/2013
3	Capsules (Microcapsules)IBA 04/2016 - 05/2007
3	Matrix Metalloproteinase 9 (Gelatinase B)IBA 12/2015 - 09/2013
3	alpha-Fetoproteins (alpha-Fetoprotein)IBA 09/2015 - 05/2007
2	AntibodiesIBA 12/2022 - 01/2020
2	Immune Checkpoint InhibitorsIBA 12/2022 - 01/2019
2	PhloretinIBA 06/2022 - 04/2020
2	Streptozocin (Streptozotocin)FDA Link 06/2022 - 01/2022
2	CollagenIBA 01/2022 - 07/2013
2	AngiotensinsIBA 01/2022 - 03/2014
2	AlkaloidsIBA 01/2022 - 01/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 01/2011
2	Bortezomib (Velcade)FDA Link 10/2021 - 11/2020
2	Mitoxantrone (Novantrone)FDA LinkGeneric 10/2021 - 11/2020
2	Eosine Yellowish-(YS) (Eosin)IBA 09/2021 - 12/2020
2	Bleomycin (Blenoxane)FDA LinkGeneric 09/2021 - 01/2021
2	Hematoxylin (Haematoxylon)IBA 09/2021 - 12/2020
2	Transcription Factors (Transcription Factor)IBA 01/2021 - 04/2015

Therapy/Procedure

29	Therapeutics 07/2022 - 12/2010
25	Hepatectomy 05/2022 - 10/2012
5	Drug Therapy (Chemotherapy) 10/2021 - 08/2013
5	Stents 01/2021 - 11/2017
4	Oral Administration 01/2020 - 02/2012
3	Radiotherapy 01/2022 - 01/2016
2	Immunotherapy 01/2022 - 01/2021
2	Subcutaneous Injections 01/2022 - 01/2011
2	Aftercare (After-Treatment) 01/2022 - 01/2015
2	Radiofrequency Ablation 12/2021 - 01/2020
2	Contraindications 01/2021 - 01/2019